ArticleEuropean journal of nuclear medicine and molecular imaging2021
Pharmacokinetic studies of [
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Article
- Digital Biopsy and Network Analysis of Dynamic [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- IntegratingCancers · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- New Approaches in Radiotherapy.Cancers · 2025Review
- Impact of different parametric Patlak imaging approaches and comparison with a 2-tissue compartment pharmacokinetic model with a long axial field-of-view (LAFOV) PET/CT in oncological patients.European journal of nuclear medicine and molecular imaging · 2025Article
- Enhancing the diagnostic capacity of [EJNMMI reports · 2024Article
- Dual-time-point dynamicAnnals of nuclear medicine · 2024Article
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- A Comparison of Arterial Input Function Interpolation Methods for Patlak Plot Analysis ofIEEE transactions on medical imaging · 2024Article
- Determining the optimal pharmacokinetic modelling and simplified quantification method of [European journal of nuclear medicine and molecular imaging · 2024Article
- Combined whole-body dynamic and static PET/CT with low-dose [European journal of nuclear medicine and molecular imaging · 2024Article
- Synthesis and Preclinical Evaluation of Two NovelMolecules (Basel, Switzerland) · 2024Article
- Comparison of tracer kinetic models forEJNMMI research · 2024Article
- Comparison of Tracer Kinetic Models for 68Ga-PSMA-11 PET in Intermediate Risk Primary Prostate Cancer Patients.Research square · 2023Article
- Direct Patlak Reconstruction of [International journal of molecular sciences · 2023Article
- Multiparametric dynamic whole-body PSMA PET/CT using [EJNMMI research · 2023Article
- Current role of PSMA-PET imaging in the clinical management of prostate cancer.Therapeutic advances in medical oncology · 2023Review
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[
methodsDynamic PET-CT over the lower abdomen and static whole-body PET-CT 80-90 min p.i. from 142 patients with biochemical recurrence were retrospectively analysed. Detection rates were compared to PSA levels. Average time-activity curves were calculated from tumour lesions and normal tissue. A three-compartment model and non-compartment model were used to calculate tumour kinetics.
resultsOverall detection rate was 70.42%, and in patients with PSA > 0.4 ng/mL 76.67%. All tumour lesions presented the steepest standardised uptake value (SUV) incline in the first 7-8 min before decreasing to different degrees. Normal tissue presented with a low uptake, except for the bladder, which accumulated activity the steepest 15-16 min. p.i.. While all tumour lesions continuously increased, bone metastases showed the steepest decline, resulting in a significantly lower SUV than lymph node metastases (60 and 80-90 min). Transport rate from the blood and tracer binding and internalisation rate were lower in bone metastases. Heterogeneity (fractal dimension) and vascular density were significantly lower in bone metastases.
conclusionEven at low PSA between 0.51 and 0.99 ng/mL, detection rate was 57%. Dynamic imaging showed a time window in the first 10 min where tumour uptake is high, but no bladder activity is measured, aiding accuracy in distinction of local recurrence. Kinetic modelling provided additional information for tumour characterisation by tissue type.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.